ClinicalTrials.Veeva

Menu

Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients

Zhejiang University logo

Zhejiang University

Status

Enrolling

Conditions

Gastric Cancer
Morbidly Obese Patients
Esophageal Cancer
Hypoxemia

Treatments

Device: COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation
Device: High-Flow Nasal Cannula Oxygenation

Study type

Interventional

Funder types

Other

Identifiers

NCT07175155
ZJU2025C140

Details and patient eligibility

About

Hypoxaemia during sedated gastrointestinal endoscopy exceeds 40 % in morbidly obese (BMI ≥ 35 kg m-²) patients. High-flow nasal cannula alone often fails because of persistent airway collapse. A recent innovation in this domain is the COMBO Endoscopy Oropharyngeal Airway-a multifaceted device that encompasses capnography monitoring, bite block , oxygenation support, and oropharyngeal airway management.The purpose of this study is to investigate whether the combination of the COMBO Endoscopy Oropharyngeal Airway and High-Flow Nasal Cannula oxygenation reduces the incidence of hypoxemia in this population.

Enrollment

410 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 years.
  • BMI ≥ 35 kg/m².
  • Patients undergoing gastroscopy or gastrointestinal endoscopy.
  • The estimated duration of the procedure does not exceed 45 minutes.
  • Patients have signed the informed consent form.

Exclusion criteria

  • Coagulation disorders or bleeding tendency (e.g., oral/nasal bleeding risk, mucosal injury, oropharyngeal obstruction) making oropharyngeal airway placement unsafe or unfeasible.
  • Active upper respiratory tract infection (oral, nasal, or pharyngeal), or fever (core temperature >37.5°C).
  • Chronic obstructive pulmonary disease or other acute/chronic pulmonary diseases requiring long-term or intermittent oxygen therapy, or preoperative SpO₂ ≤ 92% on room air.
  • Severe organ dysfunction, including: Cardiac insufficiency (<4 METs), Severe renal insufficiency (requiring dialysis), Diagnosed severe hepatic insufficiency, Increased intracranial pressure, ASA physical status ≥ IV.
  • Confirmed pregnancy or current breastfeeding.
  • Known allergy to sedatives (e.g., propofol) or medical adhesives.
  • Multiple traumatic injuries.
  • Current participation in another clinical trial.
  • Other conditions deemed unsuitable by the investigator.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

410 participants in 2 patient groups

COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation
Experimental group
Description:
In this group, patients use the COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation
Treatment:
Device: COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation
High-Flow Nasal Cannula Oxygenation
Active Comparator group
Description:
In this group, patients use the High-Flow Nasal Cannula Oxygenation
Treatment:
Device: High-Flow Nasal Cannula Oxygenation

Trial contacts and locations

4

Loading...

Central trial contact

Mingxia Xu; Diansan Su, Chief Physician

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems